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Bacterial aromatic polyketides such as tetracycline and doxorubicin are a medicinally important class of natural
products produced as secondary metabolites by actinomyces bacteria. Their backbones are derived from malonyl-CoA
units by polyketide synthases (PKSs). The nascent polyketide chain is synthesized by the minimal PKS, a module
consisting of four dissociated enzymes. Although the biosynthesis of most aromatic polyketide backbones is initiated
through decarboxylation of a malonyl building block (which results in an acetate group), some polyketides, such as the
estrogen receptor antagonist R1128, are derived from nonacetate primers. Understanding the mechanism of
nonacetate priming can lead to biosynthesis of novel polyketides that have improved pharmacological properties.
Recent biochemical analysis has shown that nonacetate priming is the result of stepwise activity of two dissociated PKS
modules with orthogonal molecular recognition features. In these PKSs, an initiation module that synthesizes a starter
unit is present in addition to the minimal PKS module. Here we describe a general method for the engineered
biosynthesis of regioselectively modified aromatic polyketides. When coexpressed with the R1128 initiation module,
the actinorhodin minimal PKS produced novel hexaketides with propionyl and isobutyryl primer units. Analogous
octaketides could be synthesized by combining the tetracenomycin minimal PKS with the R1128 initiation module.
Tailoring enzymes such as ketoreductases and cyclases were able to process the unnatural polyketides efficiently.
Based upon these findings, hybrid PKSs were engineered to synthesize new anthraquinone antibiotics with predictable
functional group modifications. Our results demonstrate that (i) bimodular aromatic PKSs present a general
mechanism for priming aromatic polyketide backbones with nonacetate precursors; (ii) the minimal PKS controls
polyketide chain length by counting the number of atoms incorporated into the backbone rather than the number of
elongation cycles; and (iii) in contrast, auxiliary PKS enzymes such as ketoreductases, aromatases, and cyclases
recognize specific functional groups in the backbone rather than overall chain length. Among the anthracyclines
engineered in this study were compounds with (i) more superior activity than R1128 against the breast cancer cell line
MCF-7 and (ii) inhibitory activity against glucose-6-phosphate translocase, an attractive target for the treatment of
Type II diabetes.
Introduction
Polyketides are a large class of structurally and pharmaco-
logically diverse molecules, including many antibiotics and
antitumor drugs (O’Hagan 1991). They are produced as
secondary metabolites primarily by bacteria and fungi (Hop-
wood 1997). Analogous to fatty acid synthases (FASs),
polyketide synthases (PKSs) catalyze the biosynthesis of
polyketides through repetitive C–C bond-forming reactions
between selected acyl-CoA-derived building blocks (Cane et
al. 1998). However, in contrast to fatty acid biosynthesis, the
carbon chain backbones of polyketides exhibit greater variety
with respect to the choice of acyl-CoA building blocks and the
degree of reduction of b-ketone functional groups that result
after each round of chain elongation.
In complex polyketides, such as the macrolide erythromy-
cin, biosynthetic variability arises from independent control
of each round of chain elongation by one module of enzymes
within a multimodular PKS (Cane et al. 1998). (The term
module used in this report refers to a collection of dissociated
enzymes. The elongation module consists of enzymes involved
in chain extension steps of polyketide biosynthesis, while the
initiation module consists of enzymes involved in the
nonacetate priming of certain aromatic PKSs.) However, the
polyketide backbones of most bacterial aromatic polyketides
(Figure 1) are synthesized by a single dissociated enzymatic
module comprised of a heterodimeric ketosynthase–chain
length factor (KS-CLF) complex that catalyzes chain initiation
and iterative elongation, an acyl-carrier protein (ACP) that
shuttles malonyl extender units to the active site of KS-CLF as
malonyl-S-ACP intermediates, and a malonyl-CoA:ACP acyl
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PLoS BIOLOGYtransferase (MAT), which catalyzes acyl transfer between
malonyl-CoA and the ACP and is shared between the PKS and
the housekeeping FAS(s) (Revill et al. 1995; Khosla et al. 1999).
For example, the minimal PKS from the actinorhodin (act)
biosynthetic pathway synthesizes an octaketide (C16) back-
bone from eight malonyl-CoA equivalents, whereas the
tetracenomycin (tcm) minimal PKS synthesizes a decaketide
(C20) backbone from ten equivalents of malonyl-CoA (Figure
2) Although a large number of ‘‘unnatural’’ natural products
have been engineered to date by genetic manipulation of
bacterial aromatic PKSs (Khosla and Zawada 1996; Rawlings
1999; Shen et al. 1999), most of this variety has resulted from
the combinatorial manipulation of ketoreductases (KRs),
aromatases (AROs), and cyclases (CYCs) that ordinarily
interact with minimal PKS subunits to channel the excep-
tionally high reactivity of a poly-b-ketone intermediate
(Figure 2) into the observed natural product (McDaniel et
al. 1995). The development of generally applicable methods
for chemo- and regioselective modiﬁcation of natural and
unnatural bacterial aromatic polyketides is an important goal
for the medicinal chemist and, more recently, the biosyn-
thetic engineer.
The primer unit of a polyketide backbone is an attractive
site for introducing unnatural building blocks. For example,
genetic and chemobiosynthetic approaches have been devised
to replace the natural primer units in the polyketide
backbones of erythromycin, avermectin, and rapamycin with
a broad range of unnatural functional groups (Jacobsen et al.
1997; Marsden et al. 1998; Lowden et al. 2001; Long et al.
2002). However, most aromatic PKSs initiate polyketide
biosynthesis through decarboxylation of malonyl-ACP, re-
sulting in an invariant acetyl primer unit (Figure 2A) (Bisang
et al. 1999; Dreier and Khosla 2000). Important antitumor
antibiotics, such as the anthracycline doxorubicin, are
primed with propionate units. Recently, we have investigated
the biosynthesis of the estrogen receptor antagonist R1128
(Hori et al. 1993) and the antiparasitic agent frenolicin (Bibb
et al. 1994), two aromatic polyketides that are apparently
derived from nonacetate primer units (see Figure 1). These
bimodular PKSs are comprised of a dissociated initiation
module consisting of a homodimeric KS (ZhuH, named for
R1128 PKS), an acyl transferase (AT) (ZhuC), and an ACP
(ZhuG), and an elongation module consisting of a KS-CLF
(ZhuA–ZhuB), a second ACP (ZhuN), and the MAT (borrowed
from the housekeeping FAS). The proposed biosynthetic
mechanism of the R1128 PKS is shown in Figure 3 (Marti et al.
2000). Biochemical studies have revealed that the KS subunits
of the initiation and elongation modules have speciﬁc
protein–protein interactions with ACPs from the same
module (Tang et al. 2003), suggesting that it may be possible
to functionally coexpress these initiation modules with
heterologous minimal PKSs, so as to regioselectively incor-
porate nonacetate primer units into aromatic polyketides. Of
particular interest is the R1128 initiation module, since it is
known to have broad substrate speciﬁcity (Meadows and
Khosla 2001) and the X-ray crystal structure of its KS subunit
has been solved (Pan et al. 2002). Here we demonstrate the
biosynthetic utility of the R1128 initiation module by
synthesizing a variety of anthraquinone antibiotics, some
with signiﬁcant biological activities. In the course of these
studies, fundamentally novel and unanticipated properties of
bacterial aromatic PKSs have been elucidated.
Results
Using the host/vector system ﬁrst described by McDaniel et
al. (1993a), several combinations of initiation modules,
minimal PKSs, and auxiliary PKS subunits were coexpressed
and analyzed. Streptomyces coelicolor CH999, which contains a
chromosomal deletion of the entire act gene cluster, was used
as the host strain, whereas the shuttle vector pRM5 was used
as an expression plasmid. The polyketide product proﬁles of
the recombinant strains are summarized in Table 1.
Recombination of an Initiation Module and a
Heterologous Minimal PKS
Guided by our recent observation that the KS–ACP pairs of
initiation and elongation PKS modules have orthogonal
molecular recognition features, we ﬁrst attempted to coex-
press the R1128 initiation module with the act minimal PKS.
The zhuC (AT), zhuH (KS), and zhuG (ACP) genes from the
R1128 gene cluster were coexpressed with the genes encoding
the act KS-CLF, ZhuN (ACP), and the act KR (on plasmid
pYT46). Control plasmids pYT44, lacking the R1128 initiation
module, and pYT45, lacking zhuN, were also constructed and
characterized. All three plasmids were introduced into S.
coelicolor CH999 by transformation, and polyketides products
were analyzed by liquid chromatography/mass spectrometry
(LC/MS) and nuclear magnetic resonance (NMR) spectro-
scopy.
S. coelicolor CH999/pYT44 produced mutactin (and its
dehydrated derivative, dehydromutactin), the expected prod-
ucts of the act minimal PKS in the presence of act KR
(McDaniel et al. 1994a), whereas CH999/pYT45 did not
produce any polyketide, consistent with the requirement
for separate ACPs to support turnover of the initiation and
Figure 1. Examples of Aromatic Polyketides
Actinorhodin (S. coelicolor) and tetracenomycin (S. glaucescens) are
primed by acetate groups through decarboxylation of malonyl-CoA.
Actinorhodin and tetracenomycin are synthesized by the act and tcm
PKSs, respectively. Oxytetracycline (S. rimosus), frenolicin (S. rose-
ofulvus), R1128 (S. R1128), and doxorubicin (S. peucetius) are primed by
nonacetate units as shown. Notably, R1128 family of compounds (a–d)
are primed with different alkyl units. Oxytetracycline, frenolicin,
R1128, and daunorubicin are synthesized by the otc, frn, R1128, and
dxr PKSs, respectively. Actinorhodin and tetracenomycin represent
much-studied models of aromatic polyketide biosynthesis. Oxy-
tetracycline is a commonly prescribed antibiotic. Frenolicin is a
potent antiparasitic agent. R1128 is an estrogen receptor antagonist
that shows minimal agonist activity. Doxorubicin is a widely used
anticancer drug in treating late-stage tumors.
DOI: 10.1371/journal.pbio.0020031.g001
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Engineered Biosynthesis of Polyketideselongation modules in a bimodular aromatic PKS (Figure 4A)
(Tang et al. 2003). Remarkably, CH999/pYT46 produced two
new polyketide products in addition to mutactin; these new
polyketides were isolated with a combined yield of 40 mg/l,
representing 70% of total polyketides produced by this host.
The two compounds had molecular masses of 278 and 292.
(The 14 mass unit difference is suggestive of one methylene
unit difference between the two compounds.) Isotopic label-
ing studies indicated that the compounds were derived from
six acetate equivalents. NMR analyses (Table 2) revealed that
the two compounds, YT46 (1) and YT46b (2), had structures
shown in Figure 4. YT46 and YT46b are identical, with the
exception of a branched methyl group in YT46b. Each
compound contains an a-pyrone moiety, which is commonly
observed in aberrantly cyclized aromatic polyketides (Yu et al.
1998). The C-9 carbonyl groups were selectively reduced by
the act KR. Supplementing the growth medium with
13C-
labeled sodium propionate revealed that the alkyl moiety of 1
was derived from propionyl-CoA. Similarly, supplementing
the growth medium with 1 g/l of L-valine resulted in a 2-fold
increase in the level of 2, suggesting the branched alkyl group
observed in 2 was derived from isobutyryl-CoA, a primary
catabolite of L-valine (Zhang et al. 1999). These ﬁndings are
consistent with in vitro characterization of the substrate
speciﬁcity of ZhuH (Meadows and Khosla 2001). Among
substrates tested, ZhuH had an 11-fold higher speciﬁcity for
both propionyl-CoA and isobutyryl-CoA over the next best
substrate, acetyl-CoA (Meadows and Khosla 2001). YT46
analogs generated by incorporation of isovaleryl and butyryl
primer units were also detectable by LC/MS, although these
compounds were present at lower levels. Dehydrated analogs
of 1 and 2 were also observed in CH999/pYT46. (Puriﬁed 1
and 2 slowly dehydrate at room temperature.)
The biosynthesis of 1 and 2 by a recombinant bimodular
PKS consisting of the act minimal PKS and the R1128
initiation module supported our hypothesis that nonace-
Figure 2. Biosynthesis of Acetate-Primed
Polyketides
(A) Minimal PKS is necessary and sufﬁ-
cient for the synthesis of a complete
polyketide chain. KS-CLF is the con-
densing enzyme in the minimal PKS,
catalyzing each round of condensation
between malonyl-ACP and the growing
polyketide chain. ACP serves as the
carrier for malonyl units, and it is
malonylated by the MAT associated with
FAS. Chain synthesis initiates with the
decarboxylation of malonyl-ACP to ace-
tyl-ACP by the KS-CLF for most aro-
matic PKSs. The acetyl unit is then
transferred to the KS-CLF and primes
the enzyme for subsequent condensa-
tions. The overall chain length is con-
trolled by the KS-CLF complex. An
octaketide synthase (e.g., act PKS) uses a
total of eight malonyl equivalents (in-
cluding the primer), while a decaketide
synthase (e.g., tcm PKS) uses a total of ten
malonyl equivalents.
(B) An octaketide can spontaneously
form SEK4 and SEK4b in the absence
of tailoring enzymes. Members of the act
KR family can regioselectively reduce the
octaketide at C-9, which can then spon-
taneously form mutactin in the absence
of AROs and CYCs. When bifunctional
ARO/CYC (e.g., actVII) and second-ring
CYC (e.g., actIV) are present, the reduced
octaketide can be transformed into the
anthraquinone DMAC.
(C) A decaketide can spontaneously form
SEK15 and SEK15b in the absence of
tailoring enzymes. KR can regioselec-
tively reduce the C-9 carbonyl. A re-
duced decaketide can spontaneously
form RM20, RM20b, and RM20c. Not
shown are the other tailoring enzymes
associated with decaketides, which can
transform the nascent decaketide into
tetracycline or anthracycline structures.
DOI: 10.1371/journal.pbio.0020031.g002
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natorial expression of heterologous initiation and elongation
PKS modules from bacterial aromatic PKSs. Indeed, the act
KS-CLF, which is normally primed exclusively by acetate
(generated via decarboxylation of a malonyl unit), has a
remarkably strong preference for the diketide product of the
R1128 initiation module. However, unexpectedly, the incor-
poration of a longer chain substrate into the catalytic cycle of
the act minimal PKS results in a reduced number of malonyl
units utilized during iterative chain extension (Figure 4B).
Compound 1 is a hexaketide whose backbone consists of 15 C
atoms. Thus, upon introduction of an initiation PKS module
into the overall catalytic cycle, the octaketide synthase retains
its carbon chain length speciﬁcity, rather than executing the
normal number of extension cycles. In contrast, the act KR
retains its selectivity for the C-9 carbonyl in the nascent
polyketide backbone, notwithstanding structural differences
between a hexaketide and an octaketide.
In Vivo Reconstitution of R1128 Biosynthesis Using a
Heterologous Bimodular PKS
To validate the generality of the above observations, we
sought to reconstitute the biosynthesis of R1128 family of
compounds in S. coelicolor using a heterologous combination
of initiation and elongation PKS modules (Figure 5). It
follows from the above analysis that to synthesize an alkyl-
primed anthraquinone such as 3 and 4, the following catalytic
components are needed: (i) an initiation module; (ii) a
decaketide minimal PKS that can extend the ﬁve to six
carbon products of the initiation module by seven more
extender units to yield a 19–20 carbon polyketide; and (iii)
appropriate ARO and CYC subunits.
The R1128 family of antibiotics represents a unique set of
anthraquinones that contain an unreduced C-9 carbonyl
(present as an enolic C-9 hydroxyl in R1128). Since members
of the act ARO/CYC family are unable to cyclize an unreduced
octaketide (McDaniel et al. 1994b) and since enzymes from
the tcm ARO/CYC family have alternative regiospeciﬁcity of
cyclization (McDaniel et al. 1995), AROs and CYCs were
sought from the R1128 biosynthetic pathway. ZhuI and ZhuJ
are two putative enzymes present in the R1128 PKS (Marti et
al. 2000). ZhuI, which is homologous to the act ARO/CYC, was
predicted to be a ﬁrst ring CYC, while ZhuJ was predicted to
be a second ring CYC. To test these hypotheses, plasmids
pYT105 and pYT92 (see Table 1) were constructed, coex-
pressing ZhuI and ZhuJ with the act minimal PKS and the tcm
minimal PKS, respectively. Analysis of compounds produced
by CH999/pYT92 revealed the decaketides SEK15 and
SEK15b as the major products, suggesting ZhuI and ZhuJ
did not recognize an unreduced decaketide. However, the
anthraquinone compound (Bartel et al. 1990), 3,6,8-trihy-
droxy-1-methylanthraquinone-2-carboxylic acid (TMAC) (7;
also known as laccaic acid D, a well known plant-derived
pigment) (Figure 5A; Table 2; atoms are numbered according
Figure 3. Proposed Priming Mechanisms for R1128 PKS
An independent loading module consisting of ZhuG, ZhuH, and
ZhuC can generate an alkylacyl-ZhuG intermediate (boxed) from
malonyl-CoA and short chain acyl-CoAs such as propionyl-CoA and
isobutyryl-CoA. The precursor selectivity is determined by the KSIII
analog ZhuH. Ketoreductase, dehydratase, and enoylreductase
associated with FAS are presumed to transformed the b-ketoacyl-
ZhuG moiety into alkylacyl-ZhuG. The alkylacyl-ZhuG is then able to
prime the minimal PKS module (consisting of the ZhuB [KS], ZhuA
[CLF], ACP [ZhuN], and MAT) and initiate polyketide synthesis. The
mechanism by which the transacylation occurs is not known and is
possibly catalyzed by unassigned, but essential, enzyme ZhuC.
Homologs of ZhuG, ZhuH, and ZhuC are present in the frn PKS
(FrnJ, FrnK, and FrnI, respectively) as well.
DOI: 10.1371/journal.pbio.0020031.g003
Table 1. Plasmids Constructions and Resulting Polyketide Products
Plasmid R1128 LM
a Minimal PKS
b KR (actIII) ARO, CYC Polyketide Products
pYT44 – act þ – Mutactin
pYT45 þ –
c þ –N P
d
pYT46 þ act þ – 1, 2 (70%)
e Mutactin
pYT92 – tcm – ZhuI, ZhuJ SEK15, SEK15b
pYT105 – act – ZhuI, ZhuJ 7 (30%) SEK4, SEK4b
pYT128 þ tcm – ZhuI, ZhuJ 3–6 (50%) SEK15, SEK15b
pYT90 – tcm þ actVII, actIV RM20, RM20b, RM20c
pYT127 þ tcm þ actVII, actIV 8–11 (70%) RM20, RM20b, RM20c
Each plasmid is a derivative of pRM5. The constructs are transformed into S. coelicolor strain CH999. Produced are analyzed by LC/MS and NMR.
aLM: Loading module, consists of ZhuC, ZhuH, and ZhuG.
bThe minimal PKS consists of the indicated KS-CLF, ZhuN, and the endogenous MAT.
cThis construct contains the act KS-CLF, but lacks the minimal ACP ZhuN.
dNP: no major polyketide product observed.
eNumber in parenthesis indicates yield of the product as percentage of total polyketide recovered.
DOI: 10.1371/journal.pbio.0020031.t001
PLoS Biology | http://biology.plosjournals.org February 2004 | Volume 2 | Issue 2 | Page 0230
Engineered Biosynthesis of PolyketidesFigure 4. Engineered Biosynthesis of YT46
(1) and YT46b (2)
(A) HPLC trace of extracts from CH999/
pYT44-pYT46. A linear gradient of
20%–60% CH3CN in water was used.
(Left) CH999/pYT44, which only has the
minimal PKS module from act PKS and
KR, produced the expected mutactin
(and the dehydrated dehydromutactin).
CH999/pYT45, which contains the R1128
loading module and an incomplete min-
imal PKS, produced no major polyke-
tides. (Right) Upon coexpressing the
R1128 loading module with a functional
act minimal PKS (in the presence of KR),
two new major polyketides were pro-
duced with the indicated masses. When 1
g/l of valine was added to the growth
medium, the yield of the compound with
mass of 292 doubled (traces not drawn to
the same scale). The two compounds are
identiﬁed as YT46 and YT46b.
(B) Engineered biosynthesis of YT46 and
YT46b. YT46 (1) is derived from propi-
onate, while YT46b (2) is derived from
isobutyrate. Alkylacyl-ZhuG supplied by
the loading module is able to prime the
act minimal PKS efﬁciently. Incorpora-
tion of the alkylacyl moiety by the KS-
CLF led to a decrease in the number of
extender units incorporated in the ﬁnal
chain. The octaketide synthase is now
only able to synthesize an alkyl hexake-
tide. The KR is able to regioselectively
reduce the alkyl-hexaketide at the ex-
pected C-9 position. The reduced hex-
aketide spontaneously form the novel
bicyclic structure observed in 1 and 2.
Dehydrated versions of 1 and 2 are also
observed (outside of limits shown in [A]).
DOI: 10.1371/journal.pbio.0020031.g004
Table 2. Proton and Carbon NMR Data for YT46 (1) and YT46b (2)
Number
a YT46 (1) YT46b (2)
b
13C d (ppm)
1H d (ppm) (m, JHH [Hz], area)
13C d (ppm), (Jcc [Hz])
1H d (ppm) (m, JHH [Hz], area)
1 164.0 164.5 (78.8)
2 89.8 5.24 (d, 2.1, 1H) 90.4 (78.9) 5.24 (d, 2.1, 1H)
3 169.9 170.5 (57)
4 104.2 5.85 (d, 2.1, 1H) 104 (58.2) 5.86 (d, 2.1, 1H)
5 158.6 159.2 (68.0)
6 130.8 131.4 (68.0)
7 194.3 194.9 (40.1)
8 46.3 2.76 (dd, 18, 4.1, 1H)
2.50 (dd, 17.1, 6.7, 1H)
47.0 (40.1) 2.76 (dd, 18, 4.1, 1H)
2.51 (dd, 17.1, 6.7, 1H)
9 65.2 4.18–4.24 (m, 1H) 65.8 (36.4) 4.18–4.24 (m, 1H)
10 38.6 2.61 (dd, 16.5, 3.7, 1H)
2.40 (dd, 17.2, 8.1, 1H)
39.5 (36.5) 2.61 (dd, 16.5, 3.7, 1H)
2.40 (dd, 17.2, 8.1, 1H)
11 163.3 164.2 (40.1)
12 35.5 2.23 (t, 7.8, 2H) 34.5 (40.1) 2.22 (t, 8.1, 2H)
13 29.6 1.41–1.52 (m, 2H) 28.8 1.33–1.40 (m, 2H)
14 22.4 1.20–1.31 (m, 2H) 37.3 1.44–1.52 (m, 1H)
15, 159 13.2 0.79 (t, 7.2, 3H) 22.4 0.78 (d, 6.4, 6H)
Spectra were obtained at 400 MHz for proton and 100 MHz for carbon and were recorded in acetone-d6.
aCarbons are labeled as shown in Figure 4B.
b1, 2-
13C-acetate labeling experiments were performed with 2 and the observed carbon–carbon coupling constants are shown in parenthesis.
DOI: 10.1371/journal.pbio.0020031.t002
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Engineered Biosynthesis of Polyketidesto order in polyketide backbone), was isolated from CH999/
pYT105 at 10 mg/l, in addition to the known products of act
minimal PKS, SEK4 and SEK4b (20 mg/l). Thus, ZhuI and ZhuJ
are able to cyclize an unreduced octaketide into the
corresponding anthraquinone. The incomplete transforma-
tion of nascent octaketides into TMAC may be due to the fact
that an acetate-primed octaketide is not a natural substrate of
the two CYCs (see below).
The identiﬁcation of ZhuI and ZhuJ as the appropriate
CYCs for the synthesis of R1128-like anthraquinones promp-
ted the design of pYT128, which coexpresses tcm KS-CLF,
ZhuN, ZhuI, ZhuJ, and the R1128 initiation module. Plasmid
pYT92 (which lacks the initiation module) was used as the
negative control. In addition to the decaketides SEK15 and
SEK15b, two new anthraquinone compounds, YT128 (3) and
YT128b (4), were isolated at comparable levels (7 mg/l each)
from S. coelicolor CH999/pYT128. The two compounds account
for 50% of total polyketides produced by this recombinant
strain. [
13C]Propionate and valine feeding experiments
veriﬁed the alkyl groups installed at C-16 were indeed
derived from either propionyl-CoA or isobutyryl-CoA. NMR
and MS analyses conﬁrmed the identities of 3 and 4 as alkyl-
primed TMAC analogs (Table 3). The natural products,
R1128b (5) and R1128c (6) (i.e., decarboxylated derivatives
of 3 and 4), were present at an approximately 20% level to
that of 3 and 4.
The engineered biosynthesis of compounds 3–6 further
validated our hypothesis that the initiation module of the
R1128 PKS could productively interact with elongation
modules from any bacterial aromatic PKS. Moreover, by
incorporating a primer unit with at least ﬁve carbon atoms,
the tcm KS-CLF effectively became an octaketide synthase
with respect to the rest of the polyketide molecule. This was
analogous to the conversion of the act KS-CLF into a
hexaketide synthase in the presence of the R1128 initiation
module. It also suggested that the R1128 KS-CLF was
intrinsically a decaketide synthase. Finally, analogous to the
act KR, ZhuI and ZhuJ were programmed to recognize full-
length polyketide chains based upon the number of b-
carbonyl groups, rather than the carbon chain length of the
backbone. Our ﬁndings below suggest this is a general
property for all CYCs. It should be noted that the CYCs ZhuI
and ZhuJ were apparently more efﬁcient in processing the
unreduced alkyl-primed octaketide than an acetate-primed
octaketide, since no alkyl-primed analogs of SEK4 and SEK4b
were observed in extracts of CH999/pYT128. (In the absence
of ZhuI and ZhuJ, alkyl-primed versions of both SEK4 and
SEK4b are the major polyketides produced [data not shown]).
Engineered Biosynthesis of Novel Anthraquinones Using
Bimodular PKSs
To demonstrate the utility of hybrid bimodular PKSs for
the rational design of new analogs of known polyketides, we
targeted the engineered biosynthesis of alkyl-primed 3,8-
dihydroxy-methylanthraquinone carboxylic acid (DMAC)
analogs 8 and 9 (Figure 6). Speciﬁcally, we inserted the act
KR gene into pYT128, along with replacing zhuI and zhuJ with
genes encoding act ARO and act CYC, to arrive at the plasmid
pYT127. We rationalized that the act CYCs should be able to
recognize the reduced, alkyl-primed octaketide. A control
plasmid (pYT90) lacking the R1128 initiation module was also
constructed, transformed, and analyzed.
In the absence of the initiation module, the tcm minimal
P K So u t ﬁ t t e dw i t ht h eact KR produced the expected
polyketides RM20, RM20b, and RM20c (McDaniel et al.
1993a). The targeted anthraquinone carboxylic acids 8 and
9 were isolated at high titers (15 mg/l each, 70% of total
polyketide products) in CH999/pYT127. The identities of 8
and 9 were veriﬁed by NMR and MS (Table 4). Decarboxylated
analogs of both compounds were also observed; these
compounds are alkyl-primed analogs of the natural product
aloesaponarin II. These ﬁndings conﬁrmed that, analogous to
ZhuI and ZhuJ, the act KR, act ARO, and act CYC were able to
process the octaketide intermediate possessing unnatural
functional groups at C-16. Thus, it appears that the substrate
recognition features of all auxiliary PKS subunits have
evolved to monitor the number of b-ketone functional
groups present in the polyketide chain.
Cytotoxic Properties of Novel Anthraquinones
As described above, the biosynthetic engineering methods
reported here have yielded practical routes for the produc-
tion of several new as well as known anthraquinone
Figure 5. Engineered Biosynthesis of TMAC (7), YT128 (3), and YT128b (4)
(A) ZhuI and ZhuJ are CYCs speciﬁc for unreduced octaketides.
CH999/pYT105, which coexpressed ZhuI and ZhuJ from the R1128
PKS with the act minimal PKS, produced the anthraquinone
compound TMAC (7). ZhuI and ZhuJ are thus able to cyclize
unreduced octaketides. Previously characterized octaketide CYCs
act ARO/CYC and act CYC are speciﬁc for reduced octaketides only.
ZhuI and ZhuJ are used for reconstituting R1128 biosynthesis.
(B) Reconstitution of R1128 biosynthesis using the heterologous
combination of tcm minimal PKS, R1128 loading module, and CYCs
ZhuI and ZhuJ. The alkylacyl-ZhuG intermediate synthesized by the
loading module is able to prime the decaketide synthase from tcm
minimal PKS. Owing to backbone size restrictions, the tcm KS-CLF
primed with the alkylacyl groups are only able to extend the
polyketide by seven additional malonyl units, resulting in an alkyl-
octaketide. ZhuI and ZhuJ are able to transform the unreduced
octaketide into YT128 (3) and YT128b (4). The decarboxylated
versions of 3 and 4, which are R1128b (5) and R1128c (6), respectively,
are also observed in the extracts of CH999/pYT128.
DOI: 10.1371/journal.pbio.0020031.g005
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products as pharmacologically active molecules, compounds
3, 4, 9, and DMAC were assayed for cytotoxic activities against
human mammary adenocarcinoma MCF-7 cells. Apoptosis
was observed after 24 h of drug treatment, and IC50 values
were recorded after 5 d of drug addition. The IC50 values for
reduced compounds DMAC and 9 are 26.9 and 21.7 lg/ml,
respectively, while the IC50 values for unreduced anthraqui-
nones 3 and 4 are 3.4 and 1.7 lg/ml, respectively. Thus
inserting the hydroxyl group at C-9 results in a 10-fold
increase in cytotoxic activity. The new compounds also show
modest improvement in cytotoxic activity relative to the
natural products 5 (R1128b, IC50 = 9.5 lg/ml) and 6 (R1128c,
IC50=6.2 lg/ml) (Hori et al. 1993), suggesting an additive
effect of both the C-9 OH and C-2 COOH groups.
Inhibition of glucose-6-phosphatase. Recently, the natural
product mumbaistatin (Figure 7A) was identiﬁed as an
extremely potent inhibitor (IC50 = 5 nM) of the glucose-6-
phosphate translocase enzyme complex, an attractive target
for the treatment of Type II diabetes (Vertesy et al. 2001). The
core of mumbaistatin consists of an anthraquinone moiety
that is related to several engineered compounds discussed in
this report. For example, the carboxylic acid at position C-1
and the reduced C-9 are identical to those present in
compounds DMAC, 8,a n d9. We tested the inhibitory
activities of some of these polyketides against glucose-6-
phosphate translocase using intact male rat liver microsomes.
The integrity of the microsomes was ﬁrst veriﬁed by
comparing the glucose-6-phosphatase (G6Pase) activity in the
presence of either glucose-6-phosphate or mannose-6-phos-
phate. The activity of G6Pase was then measured in the
presence of chlorogenic acid (IC50 = 0.26 mM), DMAC, 3, 4, 7,
8,o r9 using a colorimetric assay described earlier (Arion
1989) (Figure 7B). Dose-dependent inhibition was observed in
the 10–50 lM range with the alkylacyl-primed compounds 3,
Table 3. Proton and Carbon NMR Data for TMAC (7), YT128 (3), and YT128b (4)
Number
a TMAC (7) YT128 (3) YT128b (4)
13C d (ppm)
1H d (ppm)
(m, JHH [Hz], area)
1H d (ppm)
(m, JHH [Hz], area)
13C d (ppm)
1H d (ppm)








8 109.4 7.00 (d, 2.4, 1H) 7.00 (d, 2.4, 1H) 109.4 7.00 (d, 2.4, 1H)
9 166.3 – – 166.4 –






16 21.1 2.81 (s, 3H) 3.32–3.38 (m, 2H) 41.1 3.34–3.40 (m, 2H)
17 – – 1.50–1.60 (d, 2.1, 2H) 30.4 1.42–1.52 (d, 2.1, 2H)
18 – – 1.40–1.48 (m, 2H) 31.6 1.63–1.72 (m, 1H)
19, 199 – – 0.89 (t, 7.2, 3H) 22.9 0.91 (d, 6.4, 6H)
Spectra were obtained at 400 MHz for proton and 100 MHz for carbon and were recorded in methanol-d4.
aCarbons are labeled as shown in Figure 5.
DOI: 10.1371/journal.pbio.0020031.t003
Figure 6. Engineered Biosynthesis of DMAC Analogs YT127 (8) and
YT127b (9)
When the bimodular PKS containing tcm minimal PKS and R1128
loading module are coexpressed with tailoring enzymes KR, act ARO/
CYC, and act CYC, the desired compounds 8 and 9 were produced.
The decarboxylated versions of 8 and 9 are 10 and 11, respectively. All
three tailoring enzymes are able to process the unnatural alkyl-
octaketide.
DOI: 10.1371/journal.pbio.0020031.g006
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Engineered Biosynthesis of PolyketidesTable 4. Proton and Carbon NMR Data for YT127 (8) and YT127b (9)
Number
a YT127 (8) YT127b (9)
1H d (ppm)
(m, JHH [Hz], area)
13C d (ppm)
1H d (ppm)








8 7.59(dd, 8.0, 1.2, 1H) 119.2 7.60 (dd, 8.0, 1.2, 1H)
9 7.52 (t, 8.0, 1H) 136.4 7.53 (t, 8.0, 1H)






16 3.31–3.39 (m, 2H) 40.9 3.34–3.42 (m, 2H)
17 1.50–1.6 (m, 2H) 30.4 1.42–1.52 (m, 2H)
18 1.40–1.48 (m, 2H) 31.7 1.64–1.73 (m, 1H)
19, 199 0.90 (t, 7.2, 3H) 23.0 0.93 (d, 6.4, 6H)
Spectra were obtained at 400 MHz for proton and 100 MHz for carbon and were recorded in methanol-d4.
aCarbons are labeled as shown in Figure 6.
DOI: 10.1371/journal.pbio.0020031.t004
Figure 7. Inhibition of Glucose-6-Phos-
phate Translocase Activity by Anthraqui-
nones
(A) The chemical structure of mumbais-
tatin. Mumbaistatin is an extremely
potent inhibitor of glucose-6-phosphate
translocase (IC50 = 5 nM). The core of
the molecule is a reduced carboxylic acid
containing anthraquinone, which is also
observed in compounds such as DMAC,
YT127, and YT127b.
(B) Inhibition of glucose-6-phosphate
translocase activity by novel anthraqui-
nones. The inhibition assay is performed
as described in the experimental section.
The control contains the rat liver micro-
some and glucose-6-phosphate only.
Chlorogenic acid (IC50 = 0.26 mM) was
used as a reference. The G6Pase activity
of the microsome in the presence of six
anthraquinones (DMAC, 3, 4, 7, 8, and 9)
was measured. For each compound,
three different concentrations (50, 25,
and 12.5 mM) were used to detect dose-
dependent inhibition. No inhibition was
observed for DMAC or 7. Dose-depend-
ent inhibition was observed for com-
pounds 3, 4, 8, and 9.
DOI: 10.1371/journal.pbio.0020031.g007
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following: (i) a long substituent at C-16 in an anthraquinone is
important for targeting the membrane-bound G6Pase, and
(ii) the C-9 position of the anthraquinone can be chemically
modiﬁed without signiﬁcantly affecting the enzyme-inhibitor
interactions.
Discussion
The engineering of the primer units of macrolide anti-
biotics is a well-established strategy for generating new
natural product analogs with modiﬁed chemical and bio-
logical properties (Jacobsen et al. 1997; Marsden et al. 1998;
Moore and Hertweck 2002). In contrast, manipulation of the
ordinarily invariant acetate primer unit of bacterial aromatic
polyketides has not been recognized as a general method-
ology in biosynthetic engineering, presumably owing to the
apparently high efﬁciency with which these PKSs decarbox-
ylate malonyl extender units to generate acetate primers. An
exception to this principle has been recently demonstrated in
the case of the enterocin PKS, which ordinarily incorporates
a benzoic acid primer unit, but can also accept a range of aryl
acids to generate substituted enterocins (Kalaitzis et al. 2003).
In this report, we have described a general method for
modifying the primer unit of any aromatic polyketide by
engineering hybrid bimodular PKSs. This method can be used
to construct hitherto undiscovered polyfunctional aromatic
scaffolds, as illustrated by compounds 1 and 2; alternatively,
regioselective modiﬁcations of known polyketides, such as 8
and 9, can be achieved. Notably, structural analysis of these
novel compounds also revealed fundamentally new proper-
ties of bacterial aromatic PKSs, as summarized below.
The KS-CLF Prefers Nonacetate Priming over
Decarboxylative Priming
Most bacterial aromatic PKSs catalyze chain initiation by
decarboxylating an ACP-bound malonyl extender unit to
yield an acetyl primer unit, a reaction that is catalyzed by the
KS-CLF. In order to install nonacetate primer units in an
aromatic polyketide backbone, one must bypass this decar-
boxylative priming mechanism. Genetic and enzymological
analysis of the R1128 PKS, which utilizes a range of
nonacetate primer units, has revealed the existence of two
PKS modules. Each module includes a distinct KS and an
ACP. Previous studies have shown that these two KS-ACP
pairs have orthogonal molecular recognition features, leading
to the speculation that the initiation module may be able to
productively interact with other bacterial aromatic PKSs to
synthesize hybrid polyketides. However, the ability of the
R1128 initiation module to kinetically compete with the
intrinsic decarboxylative priming mechanism of the heterol-
ogous PKS was unexplored. To address this question, we
coexpressed the entire R1128 initiation module with either
the act or the tcm minimal PKS. The efﬁcient biosynthesis of
compounds described in this report shows that, although
decarboxylation cannot be completely suppressed, both PKSs
have an intrinsic preference for nonacetate primers over
decarboxylative chain initiation. It should be noted that
although acetate-primed products are observed in conjunc-
tion with nonacetate-primed compounds (e.g., CH999/pYT46
cosynthesizes mutactin along with compounds 1 and 2), the
former class of products may not be derived via decarbox-
ylative priming in strains carrying bimodular PKSs. Instead,
they may arise as a result of premature diketide transfer from
the initiation module to the elongation module before the b-
carbonyl can be reduced. Future isotope labeling studies on
such systems should be useful for quantifying the distribution
between polyketide chains derived from bimodular PKSs
versus those that arise via decarboxylative priming.
Our ﬁndings are consistent with the fact that the frenolicin
PKS from Streptomyces roseofulvus can synthesize both nanao-
mycin (an acetate-primed aromatic polyketide) and frenolicin
(its butyrate-primed analog) (Tsuzuki et al. 1986). They also
explain earlier observations that the doxorubicin (a propio-
nate-primed polyketide) and oxytetracycline (a malonamate-
primed polyketide) minimal PKSs yield acetate-primed
polyketides, when expressed alone (Fu et al. 1994; Rajgarhia
et al. 2001). Thus, notwithstanding its widespread prevalence,
decarboxylative priming by the KS-CLF can be regarded as a
default mechanism for chain initiation that occurs when
alternative primer units are unavailable.
The potential for recombining naturally occurring initia-
tion and elongation PKS modules from bacterial aromatic
PKSs is enormous. Other than the R1128 biosynthetic
pathway, initiation modules with attractive primer unit
speciﬁcity can also be found in the doxorubicin, frenolicin,
enterocin, and (presumably) oxytetracycline biosynthetic
pathways. It should be possible to recombine these synthase
units with elongation modules from the act, frn, tcm, and whiE
(Yu and Hopwood 1995) PKSs (which synthesize C16–C24
backbones) to yield a range of reactive backbones whose
subsequent fates can be controlled by previously analyzed
auxiliary PKS subunits and tailoring enzymes.
Molecular Recognition Features of the KS-CLF and
Auxiliary PKS Subunits
By generating a variety of nascent and highly reactive
alkylacyl polyketide intermediates in situ, we have been able
to probe the properties of the key aromatic PKS components,
including the KS-CLF, the KR, and different subclasses of
AROs and CYCs. Such studies have provided insight as to
whether carbon chain length of the backbone or the
repetitive poly-b-ketone functionality are the primary factors
inﬂuencing the substrate speciﬁcity of these proteins.
Our results demonstrate that, since chain length speciﬁcity
of KS-CLF heterodimers is primarily dictated by the back-
bone size, incorporation of bulky, nonacetate primer units is
compensated for by a reduced number of condensation
cycles. Thus, hexaketides and octaketides are synthesized by
the act and tcm KS-CLF, respectively, when these KSs are
primed with pentanoyl (or 4-methylpentanoyl) primer units.
In contrast to KS-CLF subunits, the regioselectivity of
auxiliary PKS enzymes such as KR, ARO, and CYC is
unaffected by the incorporation of nonacetate starter units.
For example, the act KR selectively reduced the C-9 keto
group in an acetate-primed octaketide (DMAC), an alkyl-
hexaketide (see Figure 4B), and an alkyl-octaketide (see
Figure 5B). This observation conﬁrms an earlier proposal
(McDaniel et al. 1993b) that such KRs recognize fully
synthesized polyketide chains, rather than the b-ketone of a
partially elongated intermediate. Similarly, the act ARO and
CYC process a reduced (but not unreduced) octaketide,
regardless of the primer unit, although they are unable to
recognize hexaketides or decaketides. In contrast, the R1128
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regardless of the primer unit.
The Initiation Module of a Bimodular Aromatic PKS
Our studies have revealed that each initiation module
component, ZhuG (see Figure 4A), ZhuH (data not shown),
and ZhuC (data not shown) are essential for priming with a
nonacetate building block. Deletion of any of these three
genes from the constructs shown in Table 1 completely
abolishes nonacetate priming by the KS-CLF, but leaves the
decarboxylative priming mechanism intact. Although the
roles of ZhuG and ZhuH in the initiation pathway have been
reported (Meadows and Khosla 2001; Tang et al. 2003), the
role of ZhuC is unclear. ZhuC is homologous to the MAT and
was therefore putatively assigned as a second malonyl
transferase that malonylates ZhuG. However, subsequently it
was shown that MAT can malonylate ZhuG with high
efﬁciency (kcat, approximately150 s
–1) (Tang et al. 2003),
whereas ZhuC is sluggish in malonylating ACPs (at a rate
approximately ten times slower than MAT [data not shown]).
In light of these observations, we propose that ZhuC catalyzes
transacylation between the diketide-ZhuG and ZhuN, leading
to an alkylacyl-ZhuN intermediate that can then be trans-
ferred onto the KS-CLF. Future biochemical analysis may be
able to verify this property of ZhuC.
Engineered Biosynthesis of Diverse Aromatic Polyketides
via Bimodular PKSs
To further expand the repertoire of primer units that can
be introduced into aromatic polyketides using bimodular
PKSs, one could (i) alter the substrate speciﬁcity of the R1128
initiation module and/or (ii) engineer in vivo metabolic
pathways for new types of primer units. KSIII homologs
found in initiation modules serve as gatekeepers in primer
unit selection and are therefore attractive targets for protein
engineering. The X-ray crystal structure of ZhuH has recently
been solved and has led to the identiﬁcation of a binding
pocket for the acyl-CoA moiety (Pan et al. 2002). ZhuH adopts
a dimeric thiolase fold and selected residues at the interface
between the two subunits control size and ﬂexibility of the
binding pocket, preventing acyl groups larger than isovaleryl
groups from entering the pocket. The corresponding amino
acids in FrnI, the homolog to ZhuH in the frn PKS, are
occupied by bulkier residues, thus excluding acyl groups
larger than acetyl-CoA. Therefore, altering the size and
polarity of these gatekeeping residues using rational muta-
genesis and directed evolution may enlarge the repertoire of
acyl-CoA moieties recognized by KSIII enzymes.
Amino acid catabolism in S. coelicolor is the primary source
of primer units such as isobutyryl-CoA (valine) and isovaleryl-
CoA (leucine). These pathways involve transamination (cata-
lyzed by branched-chain amino acid transaminases) to
convert the amino acid into the corresponding a-ketoacid,
followed by decarboxylation (catalyzed by acyl-CoA dehydro-
genase [AcdH]) to yield the corresponding acyl-CoA (Zhang et
al. 1999). These catabolic pathways in actinomyces are
presumably tolerant of unnatural amino/a-keto acids, as
illustrated by the incorporation of a large variety of primer
units into the macrolide avermectin through precursor
feeding (Dutton et al. 1991). It may therefore be possible to
expand the repertoire of primer units in S. coelicolor by
feeding the recombinant strains, constructed as above, with
unnatural amino acids such as allylglycine, norvaline,
norleucine, and ﬂuorinated derivatives thereof. In addition,
heterologous expression of enzymes involved in the biosyn-
thesis of novel acyl-CoA moieties, such as cyclohexynoyl-CoA
(Cropp et al. 2000) and benzoyl-CoA (Xiang and Moore 2003),
can be efﬁcient sources of loading module substrates.
Successful elaboration of the corresponding acyl-CoA pri-
mers into full-length polyketides, through both KSIII-based
protein engineering and Streptomyces metabolic engineering,
can yield additional polyketide variants. Our observation that
anthracycline derivatives generated via such engineering
approaches can have improved properties over their natural
product counterparts provides further motivation to expand
the biosynthetic potential of bimodular PKSs.
Materials and Methods
Bacterial strains and general methods for DNA manipulation. S.
coelicolor strain CH999 was used as the host for transformation by
shuttle vectors. Protoplast preparation and PEG-assisted transforma-
tion were performed as described by Hopwood et al. (1985). All
cloning steps were performed in Escherichia coli strain XL-1 Blue. PCR
was performed using the pfuTurbo polymerase (Strategene, La Jolla,
California, United States). PCR products were ﬁrst cloned into
pCRBlunt vector (Invitrogen, Carlsbad, California, United States),
followed by DNA sequencing (Stanford PAN Facility, Stanford,
California, United States). Unmethylated DNA was obtained by using
the methylase-deﬁcient strain GM2163 (New England Biolabs,
Beverly, Massachusetts, United States).
Construction of plasmids. The following primers were used to








TC-39,5 9-CCGGAGACGCGTCACGGCCGAAGC-39; zhuI/zhuJ:5 9-GC-
CGTTTAAACCGAGGAGCACCCTCATGCGTC-39,5 9-
GGACTAGTCCTCCTCTTCCTGCTCG-39. The introduced restric-
tion sites are shown in italics. Genes encoding zhuC, zhuH, zhuN, zhuG,
and zhuI/zhuJ were ampliﬁed from pHU235 (Marti et al. 2000), and
genes encoding actVII/actIV were ampliﬁed from pRM5 (McDaniel et
al. 1993a). zhuC, zhuN, and zhuG were cloned as a single 2.1 kb XbaI–
PstI cassette; zhuH was cloned as a 1.3 kb PstI–PmeI cassette; actVII/
actIV (2.5 kb) and zhuI/zhuJ (1.3 kb) were each cloned as a PmeI–EcoRI
cassette. Different combinations of cassettes, as shown in Table 1,
were introduced into either pRM5 (KR-actKS/CLF), pSEK24 (actKS/
CLF), pSEK33 (tcmKS-CLF), or pRM20 (KR-tcmKS/CLF) to yield
pYT46, pYT105, pYT128, and pYT127, respectively.
Culture conditions, extraction, and small-scale analysis. The strains
were grown on R5 plates containing 50 mg/l thiostrepton at 308C for
7–10 d. Acyl-CoA precursors such as sodium propionate and valine
were added at 1 g/l when needed. For LC/MS and analytic HPLC
analysis, one plate was sufﬁcient. The plate was chopped into ﬁne
pieces and extracted with 30 ml of ethyl acetate (EA)/methanol/acetic
acid (89:10:1). The solvent was removed in vacuo and the residue was
redissolved in 1 ml of methanol. The polyketide products were
separated and detected by analytical reversed-phase HPLC using a
diode array detector at 280 and 410 nm using an Alltech (Vienna,
Virginia, United States) Econosphere C18 column (50 mm34.6 mm);
linear gradient: 20% acetonitrile (ACN) in water (0.1% TFA) to 60%
ACN in water (0.1% TFA) over 30 min; 1 ml/min. HPLC retention
times (tR, minutes) were as follows: 1: 13.8; 2: 15.4; 3: 20.4; 4: 21.8; 5:
24.9; 6: 26.4; 7: 17.1; 8: 22.8; 9: 24.4; 10: 27.7; 11: 29.4. LC/MS was
performed at the Vincent Coates Foundation Mass Spectrometry
Laboratory at Stanford University using a ThermoFinnigan (San Jose,
California, United States) quadrupole ion trap LC/MS system and
electrospray ionization (both positive and negative ionization).
Large-scale production and isolation. Sufﬁcient number of R5
plates (20–60 plates, depending on the yield of the product) streaked
with the desired CH999 strains were grown at 308C for 1 wk. The
plates were chopped into ﬁne pieces and extracted with a minimum
of 1 l of EA/methanol/acetic acid (89:10:1). The organic solvents were
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solution was ﬁltered and injected into a preparative reversed-phase
HPLC column (250 3 22.5 mm C-18 column; Alltech Econosil). A
20%–60% ACN in water (0.1 % TFA) gradient (50 min, 5 ml/min) was
used to separate the polyketide products. Fractions containing the
desired polyketides were combined and concentrated in vacuo. The
residuals were redissolved in acetone and applied to a preparative
TLC plate (20 cm320 cm, 0.25 mm E. Merck [Readington Township,
New Jersey, United States] silica gel plates [60F-254]). TLC plates
spotted with 1 (Rf = 0.34) and 2 (Rf = 0.41) were developed with EA/
methanol/acetic acid (97:2:1), while those spotted with 3 (Rf = 0.29), 4
(Rf = 0.37), 7 (Rf = 0.21), 8 (Rf = 0.34), and 9 (Rf = 0.43) were
developed with EA/hexane/acetic acid (90:10:1). The desired bands
were excised from the TLC plates and stirred in EA/methanol (10 ml,
9:1) for 2 h. The compounds were eluted from silica using the same
solvent and dried in vacuo.
NMR and MS characterization of novel compounds. NMR spectra
were recorded on Varian (Salt Lake City, Utah, United States) Inova
500 or Mercury 400 instruments and calibrated using residual
undeuterated solvent as an internal reference.
1H and
13C NMR
spectra data are shown in Tables 2–4. HRFABMS were collected
under negative ionization mode as follows: HRFABMS m/z: 1:
277.1082 (calcd for C15H17O5: 277.1076); 2: 291.1247 (calcd for
C16H19O5: 291.1232); 3: 355.0823 (calcd for C19H15O7: 355.0818); 4:
369.0981 (calcd for C20H17O7: 369.0974); 7: 313.0354 (calcd for
C16H9O7: 313.0348); 8: 339.0871 (calcd for C19H15O6: 339.0869); 9:
353.1036 (calcd for C20H17O6: 353.1025).
Cytotoxicity studies. The studies were performed as described by
Hori et al (1993). The cells were maintained at 378C and growth was
measured with the colorimetric MTT assay after each day. The IC50
values were measured after 5 d.
G6Pase activity assay. Male rat liver microsome (Sprague Dawley)
was purchased from BD Gentest
TM (Becton Dickinson, Franklin
Lakes, New Jersey, United States). Aliquots (100 ll, 2 mg/ml) in 0.25 M
sucrose were stored at –808C. Compound stock solutions were
prepared in 95% ethanol and diluted with DMSO. Glucose-6-
phosphate and mannose-6-phosphate were purchased from Sigma
(St. Louis, Missouri, United States).
The integrity of microsomes and G6Pase activity was measured
based on the colorimetric reaction of inorganic phosphate as
previously reported (Arion 1989). The enzyme reaction was initiated
by adding 3 ll of microsome to the reaction mixture, which
contained 51 ll of assay buffer (50 mM HEPES, 100 mM KCl, 2.5
mM EDTA, 2.5 mM MgCl2, and 1 mM DTT at pH 7.2), 3 ll of glucose-
6-phosphate (ﬁnal concentration, 1 mM), and 3 ll of inhibitor sample
in DMSO. The reaction mixture was incubated at room temperature,
and 13 ll of reaction mixture was taken every 10 min and quenched
with 117 ll of working solution (6:2:1 mixture of 0.42% ammonium
molybdate tetrahydrate in 1N H2SO4, 10% SDS in water, and 10%
ascorbic acid in water). The blue reduced phosphomolybdate
complex is formed after incubation at 508C for 20 min. The
absorbance was measured at 820 nm.
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